iA Global Asset Management Inc. Has $3.88 Million Stock Position in Zoetis Inc. $ZTS

iA Global Asset Management Inc. reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 18.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,852 shares of the company’s stock after selling 5,629 shares during the quarter. iA Global Asset Management Inc.’s holdings in Zoetis were worth $3,876,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Versor Investments LP acquired a new position in Zoetis during the 2nd quarter worth approximately $536,000. Triglav Investments D.O.O. raised its stake in Zoetis by 191.5% during the 2nd quarter. Triglav Investments D.O.O. now owns 13,000 shares of the company’s stock worth $2,027,000 after buying an additional 8,540 shares during the period. Welch & Forbes LLC acquired a new position in Zoetis during the 2nd quarter worth approximately $343,000. Sumitomo Life Insurance Co. raised its stake in Zoetis by 7.9% during the 2nd quarter. Sumitomo Life Insurance Co. now owns 56,290 shares of the company’s stock worth $8,778,000 after buying an additional 4,138 shares during the period. Finally, GHP Investment Advisors Inc. raised its stake in Zoetis by 152.4% during the 2nd quarter. GHP Investment Advisors Inc. now owns 2,943 shares of the company’s stock worth $459,000 after buying an additional 1,777 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS stock opened at $144.25 on Monday. The firm has a market cap of $63.93 billion, a PE ratio of 24.83, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The business has a 50 day moving average of $147.15 and a 200-day moving average of $153.44. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $183.11.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s dividend payout ratio is currently 34.42%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research reports. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. UBS Group decreased their price objective on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a report on Monday, October 20th. Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.